secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001104659-22-085446
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa licenses vixarelimab to Genentech for $100M upfront; Q2 ARCALYST rev $27M
--------------------------------------------------------------------------------

- Genentech gets worldwide rights to vixarelimab; Kiniksa receives $100M upfront/near-term and up to $600M in milestones plus tiered royalties.
- ARCALYST Q2 2022 net revenue $27.0M (vs. $7.7M Q2 2021); full-year 2022 guidance reaffirmed at $115-130M.
- Q2 net loss narrowed to $20.0M (vs. $41.6M), with cash $138.2M and no debt; cash runway into 2025 after deal close.
- Phase 2b vixarelimab trial in prurigo nodularis screening complete; data disclosure delayed beyond H2 2022.
- Proceeds to fund cardiovascular pipeline expansion; ~20 additional ARCALYST sales reps planned in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922085446/0001104659-22-085446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922085446/tm2222182d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer